GlassScriptPhysician profile
Greg James Mott
NPI 1093101750
$2,306.44
in general payments reported to CMS, 2019-2025
26 companies · $893 in 2025
The $893 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $51.15 · 2021: $82.30 · 2022: $255 · 2023: $470 · 2024: $555 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.43 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.15 | 2020-2025 | |
| Ucb, INC. | $350.61 | 2022-2025 | Cimzia, Bimzelx |
| Amgen INC. | $193.44 | 2023-2025 | Tavneos, Avsola, Amjevita |
| Novartis Pharmaceuticals Corporation | $139.50 | 2022-2025 | |
| Pfizer INC. | $97.29 | 2024-2025 | |
| Lilly USA, LLC | $88.24 | 2023-2025 | Taltz, Zepbound |
| Aurinia Pharma U.S., INC. | $81.45 | 2021-2023 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2020-2025 | Orencia |
| Janssen Biotech, INC. | $73.66 | 2020-2025 | Tremfya |
| Csl Behring | $49.28 | 2023-2025 | Hizentra, Haegarda, Privigen |
| Sandoz INC. | $39.76 | 2023-2025 | Jubbonti, Hyrimoz |
| Mallinckrodt Hospital Products INC. | $37.03 | 2024-2025 | Acthar |
| Genzyme Corporation | $35.76 | 2025 | |
| Genentech USA, INC. | $34.08 | 2024-2025 | Actemra |
| Actelion Pharmaceuticals US, INC. | $34.03 | 2024 | Uptravi, Opsumit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $31.43 | 2024 | |
| Depuy Synthes Sales INC. | $24.35 | 2024 | Orthovisc, Monovisc |
| Sobi, INC | $21.55 | 2025 | |
| Fresenius Kabi USA, LLC | $19.03 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.49 | 2023 | Ofev |
| Alexion Pharmaceuticals, INC. | $18.01 | 2025 | Strensiq |
| Mylan Institutional INC. | $16.93 | 2023 | |
| Celltrion USA INC. | $16.53 | 2023 | Yuflyma |
| Horizon Therapeutics Plc | $16.48 | 2021 | |
| Radius Health, INC. | $16.29 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Mott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.